In recent years, several clinical randomized controlled trials (RCTs) in China showed that CKI could improve symptoms caused by chronic hepatitis B and C, liver fibrosis, and cirrhosis with minimal observed side effects. This evidence concerns the gene CHKA and Cirrhosis.